@article{10902/25168,
year = {2022},
month = {2},
url = {http://hdl.handle.net/10902/25168},
abstract = {Secondary acute myeloid leukemia (sAML) comprises a heterogeneous group of patients and is associated with poor overall survival (OS). We analyze the characteristics, treatment patterns, and outcomes of adult patients with sAML in the Programa Español de Tratamientos en Hematología (PETHEMA) registry. Overall, 6211 (72.9%) were de novo and 2310 (27.1%) had sAML, divided into myelodysplastic syndrome AML (MDS-AML, 44%), MDS/myeloproliferative AML (MDS/MPN-AML, 10%), MPN-AML (11%), therapy-related AML (t-AML, 25%), and antecedent neoplasia without prior chemotherapy/radiotherapy (neo-AML, 9%). Compared with de novo, patients with sAML were older (median age, 69 years), had more Eastern Cooperative Oncology Group ?2 (35%) or high-risk cytogenetics (40%), less FMS-like tyrosine kinase 3 internal tandem duplication (11%), and nucleophosmin 1 (NPM1) mutations (21%) and received less intensive chemotherapy regimens (38%) (all P < .001). Median OS was higher for de novo than sAML (10.9 vs 5.6 months; P < .001) and shorter in sAML after hematologic disorder (MDS, MDS/MPN, or MPN) compared with t-AML and neo-AML (5.3 vs 6.1 vs 5.7 months, respectively; P = .04). After intensive chemotherapy, median OS was better among patients with de novo and neo-AML (17.2 and 14.6 months, respectively). No OS differences were observed after hypomethylating agents according to type of AML. sAML was an independent adverse prognostic factor for OS. We confirmed high prevalence and adverse features of sAML and established its independent adverse prognostic value. This trial was registered at www.clinicaltrials.gov as #NCT02607059.},
organization = {Acknowledgments: The authors would like to thank María D. García, Carlos Pastorini, Mar Benlloch, and Alba Blázquez for data collection and management.},
publisher = {American Society of Hematology},
publisher = {Blood advances 22 February 2022. Volume 6, Number 4},
title = {Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study},
author = {Martínez-Cuadrón, David and Megías-Vericat, Juan E. and Serrano, Josefina and Martínez-Sánchez, Pilar and Rodríguez-Arbolí, Eduardo and Gil, Cristina and Aguiar, Eliana and Bergua, Juan and López-Lorenzo, José L. and Bernal, Teresa and Espadana, Ana and Colorado Araujo, María de las Mercedes and Rodríguez-Medina, Carlos and López-Pavía, María and Tomo, Mar and Algarra, Lorenzo and Amigo, María-Luz and Sayas, María J. and Labrador, Jorge and Rodríguez-Gutiérrez, Juan I.},
}